• Product NameRecombinant SARS-CoV-2 3CL Protease
• Host SpeciesEscherichia coli
• Purification> 97 % by SDS-PAGE.
• Biological ActivityTest in processing.
• EndotoxinLess than 0.1 EU/ugof rSARS-CoV-2 3CL Protease as determined by LAL method.
• Calculated MW Approximately 33.8 kDa, a single non-glycosylated polypeptide chain containing 306 amino acids.
• Target Sequence SGFRKMAFPS GKVEGCMVQV TCGTTTLNGL WLDDVVYCPR HVICTSEDML NPNYEDLLIR KSNHNFLVQA GNVQLRVIGH SMQNCVLKLK VDTANPKTPK YKFVRIQPGQ TFSVLACYNG SPSGVYQCAM RPNFTIKGSF LNGSCGSVGF NIDYDCVSFC YMHHMELPTG VHAGTDLEGN FYGPFVDRQT AQAAGTDTTI TVNVLAWLYA AVINGDRWFL NRFTTTLNDF NLVAMKYNYE PLTQDHVDIL GPLSAQTGIA VLDMCASLKE LLQNGMNGRT ILGSALLEDE FTPFDVVRQC SGVTFQ
• Formulation Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.0, with 5 % Trehalose, 0.02 % Tween-20.
• Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.- 12 months from date of receipt, -20 to -70 ˚C as supplied.- 1 month, 2 to 8 ˚C under sterile conditions after reconstitution.- 3 months, -20 to -70 ˚C under sterile conditions after reconstitution.

The 3CL protease (aka 3CLpro, Mpro or "Main" Protease) from the human SARS-CoV-2 coronavirus (Severe Acute Respiratory Syndrome coronavirus 2) is a C30-type cysteine protease. 3CLpro activity is required to process the viral polyprotein into functional, mature subunits, and there are 11 or more sites of cleavage, many containing the sequence LQ[S/A/G]; the protease cleaves c-terminal to the glutamine amino acid. Along with the CoV-2 Papain-Like Protease, 3CLpro presents an attractive target for therapeutic intervention for COVID-19. Because no human proteases with a similar cleavage specificity are known, inhibitors of 3CLpro are unlikely to cause mechanism-based toxicity.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting